搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
4 天
on MSN
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
FiercePharma
2 天
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
3 天
首款!辉瑞疫苗再获FDA批准
▎药明康德内容团队编辑日前,辉瑞(Pfizer)宣布美国FDA已批准其呼吸道合胞病毒(RSV)疫苗Abrysvo(RSVpreF),用于预防18至59岁高风险个体因RSV引起的下呼吸道疾病(LRTD)。此前,该疫苗已获批用于60岁及以上的成人群体。根 ...
pharmaphorum
3 天
Pfizer gets a leg up in RSV as FDA clears jab for all adults
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...
4 天
on MSN
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...
FiercePharma
3 天
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...
2 天
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
5 天
3项关于RSV疫苗/药物最新数据公布,涉及辉瑞Abrysvo、GSK Arexvy......
近日,在洛杉矶举行的2024年美国感染性疾病周(IDWeek)会议期间,默沙东和辉瑞分别展示了其针对呼吸道合胞病毒(RSV)的预防药物新数据,并宣称这些药物对预防感染及相关住院具有强大的保护效果。IDWeek是全球感染病学领域的顶级学术盛会,每年吸引 ...
BioSpace
3 天
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.
GlobalData on MSN
3 天
FDA expands Pfizer’s RSV vaccine label to include all high-risk adults
Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.
3 天
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will expand the number of people eligible for ...
3 小时
辉瑞制药针对呼吸道合胞体病毒(RSV)的
辉瑞制药针对呼吸道合胞体病毒(RSV)的疫苗获得美国食品药品管理局(FDA)批准,用于18-59岁年龄段人群接种。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈